Accessibility Menu
Mayne Pharma Group logo

Mayne Pharma Group(ASX) MYX

Market CapA$255.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-55%
5 Year-45%
1 Year-40%
1 Month+6%
A$3.12
-3.41%
-0.11Today
Mayne Pharma Group last closing stock price
MetricPriceDate
Last closeAUD 3.122026-09-02
Mayne Pharma Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.58%AUD 3.172026-08-26
1 month+6.48%AUD 2.932026-08-03
3 month+41.18%AUD 2.212026-06-04
Year to date+0.32%AUD 3.112025-12-31
1 year-39.88%AUD 5.192025-09-02
3 year-7.42%AUD 3.372023-09-01
5 year-45.4%AUD 5.712021-09-03
Since inception-55.28%AUD 7.222007-06-29

Mayne Pharma Group Financials at a Glance

Market Cap

A$255.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$791.77M

Net Income (TTM)

-A$69.36M

EPS (TTM)

A$0.21

P/E Ratio

10.36

Dividend

A$0.00

Beta (Volatility)

0.01 (Low)

Price

A$3.12

Volume

0

Open

A$3.22

Previous Close

A$3.12

Daily Range

A$3.12 - A$3.33

52-Week Range

A$2.04 - A$6.50

Estimated Earnings Date

Feb 24, 2027

MYX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mayne Pharma Group

Mayne Pharma Group Limited operates as a specialized pharmaceutical enterprise, focusing on the global production and distribution of both proprietary and generic medicinal products. The company serves diverse markets, including Australia, New Zealand, North America, Europe, and Asia, and is organized into four divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products.

Products and Services
  • Innovative oral drug delivery technologies
  • Comprehensive contract services for pharmaceutical development
  • Distribution of products in dermatology, women's health, and infectious diseases
Growth Outlook
  • Recent quarterly revenue reached AUD 171.6 million, indicating strong market demand
  • Trailing twelve months (TTM) gross profit margin stands at 49.6%, showcasing operational efficiency
  • Expansion into new therapeutic areas is expected to drive future revenue growth
Financial Highlights
  • Net income for the latest quarter was AUD 39.4 million, reflecting a positive turnaround
  • TTM price-to-earnings ratio is 9.71, suggesting potential value for investors
  • Cash flow from operating activities was AUD 23.7 million, indicating solid cash generation
Mayne Pharma Group Limited is positioned to leverage its innovative capabilities and extensive market reach to capitalize on growth opportunities in the pharmaceutical sector. The company's focus on specialized therapeutic areas and contract services enhances its competitive edge. Recent financial performance demonstrates a recovery trajectory, with significant revenue and net income growth, making it an intriguing option for potential investors. The strong cash flow generation further supports the company's operational stability and future investment potential.
AI Generated • Aug 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

450

CEO

Aaron Gray, MBA

Website

www.maynepharma.com

Headquarters

Salisbury South, SA 5106, AU

MYX Financials

Key Financial Metrics (TTM)

Gross Margin

49.62%

Operating Margin

-14.48%

Net Income Margin

6.38%

Return on Equity

6.58%

Return on Capital

-7.90%

Return on Assets

2.69%

Earnings Yield

9.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$255.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

81.89M

Volume

0

Avg. Volume

265.39K

Financials (TTM)

Gross Profit

A$437.66M

Operating Income

-A$79.14M

EBITDA

A$50.22M

Operating Cash Flow

A$33.09M

Capital Expenditure

-A$15.22M

Free Cash Flow

A$17.87M

Cash & ST Invst.

A$82.25M

Total Debt

A$43.20M

Mayne Pharma Group Performance Analysis

Mayne Pharma Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 183,586,00016.8%
20242024-06-30AUD 388,399,000111.6%
20252025-06-30AUD 408,095,0005.1%
20262026-06-30AUD 383,676,000-6.0%
Mayne Pharma Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-316.3%
Q42025-06-30-8.5%
Q22025-12-318.7%
Q42026-06-30-19.1%
Mayne Pharma Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -3.677.3%
20242024-06-30AUD -2.19-40.3%
20252025-06-30AUD -1.19-45.8%
20262026-06-30AUD 0.21N/A
Mayne Pharma Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3180.9%
Q42025-06-30-256.0%
Q22025-12-3179.8%
Q42026-06-30316.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$171.61M

-14.4%

Gross Profit

A$83.59M

-26.0%

Gross Margin

48.71%

N/A

Market Cap

A$255.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$520.37K

N/A

Employees

491

N/A

Net Income

A$39.41M

+138.0%

EBITDA

A$2.33M

+102.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$82.25M

-44.9%

Total Debt

A$43.20M

+11.3%

Accounts Receivable

A$175.63M

-9.1%

Inventory

A$55.49M

-25.6%

Long Term Debt

A$1.55M

-95.6%

Short Term Debt

A$41.65M

+990.2%

Return on Assets

2.69%

N/A

Return on Invested Capital

-8.55%

N/A

Free Cash Flow

A$22.05M

+155.0%

Operating Cash Flow

A$23.68M

+76.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MVF.AXMonash IVF Group Limited
A$0.77+1.99%
OCC.AXOrthocell Limited
A$0.72-2.70%
DXB.AXDimerix Limited
A$0.29+0.00%
PSQ.AXPacific Smiles Group Limited
A$2.18+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$224.41+0.03%
PCGPG&E
$13.33-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.37+0.00%
NUNu Holdings
$15.40+0.07%

Questions About MYX

What is the current price of Mayne Pharma Group?

Mayne Pharma Group is trading at A$3.12 per share.

What is the 52-week range for Mayne Pharma Group?

Over the past 52 weeks, Mayne Pharma Group has traded between A$2.04 and A$6.50.

How much debt does Mayne Pharma Group have?

As of the most recent reporting period, Mayne Pharma Group reported total debt of A$43.20M.

How much cash does Mayne Pharma Group have on hand?

Mayne Pharma Group reported A$82.25M in cash and cash equivalents in its most recent financial results.

What is Mayne Pharma Group’s dividend yield?

Mayne Pharma Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services